Skip to main content

Page last checked

Goal

Peptides for immune support

The evidence here concerns specific illnesses, not general immune support in healthy adults. A large thymosin alpha-1 sepsis trial found no clear survival benefit.

Source for this answer

Source: Based on 3 compound guides · checked 2026-09-07

Source: Based on 3 compound guides · checked 2026-09-07

Researchers have studied thymosin alpha-1 in people with serious illnesses. Some countries approve it for defined uses. Those facts do not show every use sold as immune support.

The studies cover conditions such as hepatitis B, sepsis, melanoma and venous ulcers. Each result belongs to its study population and treatment setting.

At a glance

Compounds covered

3

FDA-approved for this goal

0

Being tested for this goal

0

Reported use only

1

Three compounds, and who was enrolled

Compare the diagnosis and outcome in each row. Disease-specific trials do not answer whether a healthy person benefits from general immune support.

◆ 3 compounds coveredsources shown in each row
Compounds people take for this purpose, why they use them, what human research has measured, and where the evidence comes from.
CompoundWhat people take it forWhat research showsEvidence
Thymosin alpha-1Sold for immune support: long COVID, chronic infection, and general resilience in healthy adults.Approved outside the U.S.Under the name thymalfasin it is approved in several countries, mainly for chronic hepatitis B, where a 98-patient trial gave 1.6 mg twice a week for 26 or 52 weeks. Its largest trial gave 1.6 mg every 12 hours to 1,106 people with sepsis. By day 28, 23.4% had died on the drug against 24.1% on placebo.limited human dataDose from a human trial · no FDA label
LL-37Sold for stubborn infections, for biofilms, and for gut complaints.Measured in a human studyIt has reached people twice in registered work: injected into melanoma deposits at 250 to 500 mcg, and applied to venous leg ulcers. Neither study tested an infection. FDA cited animal findings of harm to male reproduction, and of tumor-promoting activity in some tissues.limited human dataDose from a human trial · no FDA label
KPVSold for gut inflammation and for inflamed skin, as the calming fragment of a larger hormone.Reported use onlyIn mice given colitis chemically, and in colon cells in a dish, it quietens inflammatory signaling without the pigment effect of the parent hormone. FDA states it has found no data on any person receiving it, by any route.no human dose shown to workNo human dose published

1 is approved for this purpose outside the United States, but not by FDA. 1 rests on a human study that measured something in this goal. 1 rests on reported use alone, with no study behind it.

What the large sepsis trial found

The phase 3 trial enrolled 1,106 adults with sepsis; 1,089 received at least one dose and were included in the main analysis. By day 28, mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo.

The difference was not statistically significant. The trial did not show a clear survival benefit in this population. It does not settle every proposed use of the compound.

An approval in another country applies to that country’s specified use and product. It is not an FDA approval or evidence for general immune support in a healthy adult.

General immune support remains a separate question

The sources here describe treatment in people with diagnosed illnesses. They do not show a general immune benefit for healthy adults.

A disease-specific result cannot simply be applied to a well person. The outcome, dose, formulation and population all matter.

Where to go next

The grid of 32 compounds against 10 goals

32 compounds appear on at least one page here, and the grid shows on what basis each one does.

What Thymosin alpha-1 is, how it is used, and what has been studied

Thymosin alpha-1 is a thymic immunomodulatory peptide (approved outside the united states).

What LL-37 is, how it is used, and what has been studied

LL-37 is a human cathelicidin antimicrobial peptide (research compound).

How KPV differs from the rest of its class

No published human dosing schedule was found for KPV.

Where the testosterone evidence stops

Compare all 4 compounds associated with testosterone, with a source for every supported claim.

Every compound sold for skin

3 compounds are sold or prescribed for skin; the comparison shows what has actually been studied.

The sexual function table, basis by basis

Compare why people use each compound with what human studies have actually measured for sexual function.

The anxiety and depression table, basis by basis

Compare why people use each compound with what human studies have actually measured for anxiety and depression.

Every purpose covered this way is listed on the index of goals people buy peptides for.

9primary sources, each with the day we read it — open the documents used on this page